Literature DB >> 25267631

Disruption of the immune-checkpoint VISTA gene imparts a proinflammatory phenotype with predisposition to the development of autoimmunity.

Li Wang1, Isabelle Le Mercier2, Juan Putra3, Wenna Chen4, Jun Liu4, Austin D Schenk5, Elizabeth C Nowak2, Arief A Suriawinata3, Jiannan Li2, Randolph J Noelle6.   

Abstract

V domain-containing Ig suppressor of T-cell activation (VISTA) is a negative checkpoint regulator that suppresses T cell-mediated immune responses. Previous studies using a VISTA-neutralizing monoclonal antibody show that VISTA blockade enhances T-cell activation. The current study describes a comprehensive characterization of mice in which the gene for VISTA has been deleted. Despite the apparent normal hematopoietic development in young mice, VISTA genetic deficiency leads to a gradual accumulation of spontaneously activated T cells, accompanied by the production of a spectrum of inflammatory cytokines and chemokines. Enhanced T-cell responsiveness was also observed upon immunization with neoantigen. Despite the presence of multiorgan chronic inflammation, aged VISTA-deficient mice did not develop systemic or organ-specific autoimmune disease. Interbreeding of the VISTA-deficient mice with 2D2 T-cell receptor transgenic mice, which are predisposed to the development of experimental autoimmune encephalomyelitis, drastically enhanced disease incidence and intensity. Disease development is correlated with the increase in the activation of encephalitogenic T cells in the periphery and enhanced infiltration into the CNS. Taken together, our data suggest that VISTA is a negative checkpoint regulator whose loss of function lowers the threshold for T-cell activation, allowing for an enhanced proinflammatory phenotype and an increase in the frequency and intensity of autoimmunity under susceptible conditions.

Entities:  

Keywords:  autoimmunity; immune suppression; inflammation; peripheral tolerance

Mesh:

Substances:

Year:  2014        PMID: 25267631      PMCID: PMC4205642          DOI: 10.1073/pnas.1407447111

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  30 in total

Review 1.  The B7 family revisited.

Authors:  Rebecca J Greenwald; Gordon J Freeman; Arlene H Sharpe
Journal:  Annu Rev Immunol       Date:  2005       Impact factor: 28.527

2.  Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice.

Authors:  H Nishimura; T Okazaki; Y Tanaka; K Nakatani; M Hara; A Matsumori; S Sasayama; A Mizoguchi; H Hiai; N Minato; T Honjo
Journal:  Science       Date:  2001-01-12       Impact factor: 47.728

3.  Programmed death 1 ligand (PD-L) 1 and PD-L2 limit autoimmune kidney disease: distinct roles.

Authors:  Julia Menke; Julie A Lucas; Geraldine C Zeller; Mary E Keir; Xiao R Huang; Naotake Tsuboi; Tanya N Mayadas; Han Y Lan; Arlene H Sharpe; Vicki R Kelley
Journal:  J Immunol       Date:  2007-12-01       Impact factor: 5.422

4.  Differential role of programmed death-ligand 1 [corrected] and programmed death-ligand 2 [corrected] in regulating the susceptibility and chronic progression of experimental autoimmune encephalomyelitis.

Authors:  Bing Zhu; Indira Guleria; Arezou Khosroshahi; Tanuja Chitnis; Jaime Imitola; Miyuki Azuma; Hideo Yagita; Mohamed H Sayegh; Samia J Khoury
Journal:  J Immunol       Date:  2006-03-15       Impact factor: 5.422

5.  Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.

Authors:  E A Tivol; F Borriello; A N Schweitzer; W P Lynch; J A Bluestone; A H Sharpe
Journal:  Immunity       Date:  1995-11       Impact factor: 31.745

Review 6.  Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways.

Authors:  Brian T Fife; Jeffrey A Bluestone
Journal:  Immunol Rev       Date:  2008-08       Impact factor: 12.988

7.  Tissue expression of PD-L1 mediates peripheral T cell tolerance.

Authors:  Mary E Keir; Spencer C Liang; Indira Guleria; Yvette E Latchman; Andi Qipo; Lee A Albacker; Maria Koulmanda; Gordon J Freeman; Mohamed H Sayegh; Arlene H Sharpe
Journal:  J Exp Med       Date:  2006-04-10       Impact factor: 14.307

8.  Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis.

Authors:  Estelle Bettelli; Maria Pagany; Howard L Weiner; Christopher Linington; Raymond A Sobel; Vijay K Kuchroo
Journal:  J Exp Med       Date:  2003-05-05       Impact factor: 14.307

9.  The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice.

Authors:  Mohammed Javeed I Ansari; Alan D Salama; Tanuja Chitnis; R Neal Smith; Hideo Yagita; Hisaya Akiba; Tomohide Yamazaki; Miyuki Azuma; Hideyuki Iwai; Samia J Khoury; Hugh Auchincloss; Mohamed H Sayegh
Journal:  J Exp Med       Date:  2003-07-07       Impact factor: 14.307

10.  Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies.

Authors:  Yannick Bulliard; Rose Jolicoeur; Maurice Windman; Sarah M Rue; Seth Ettenberg; Deborah A Knee; Nicholas S Wilson; Glenn Dranoff; Jennifer L Brogdon
Journal:  J Exp Med       Date:  2013-07-29       Impact factor: 14.307

View more
  75 in total

Review 1.  Checkpoint Inhibitors: Applications for Autoimmunity.

Authors:  Anna S Tocheva; Adam Mor
Journal:  Curr Allergy Asthma Rep       Date:  2017-09-27       Impact factor: 4.806

2.  IgSF11 regulates osteoclast differentiation through association with the scaffold protein PSD-95.

Authors:  Hyunsoo Kim; Noriko Takegahara; Matthew C Walsh; Sarah A Middleton; Jiyeon Yu; Jumpei Shirakawa; Jun Ueda; Yoshitaka Fujihara; Masahito Ikawa; Masaru Ishii; Junhyong Kim; Yongwon Choi
Journal:  Bone Res       Date:  2020-02-10       Impact factor: 13.567

Review 3.  Rethinking peripheral T cell tolerance: checkpoints across a T cell's journey.

Authors:  Mohamed A ElTanbouly; Randolph J Noelle
Journal:  Nat Rev Immunol       Date:  2020-10-19       Impact factor: 53.106

Review 4.  VISTA: Coming of age as a multi-lineage immune checkpoint.

Authors:  M A ElTanbouly; E Schaafsma; R J Noelle; J L Lines
Journal:  Clin Exp Immunol       Date:  2020-02-04       Impact factor: 4.330

Review 5.  VISTA: a novel immunotherapy target for normalizing innate and adaptive immunity.

Authors:  Mohamed A ElTanbouly; Walburga Croteau; Randolph J Noelle; J Louise Lines
Journal:  Semin Immunol       Date:  2019-04       Impact factor: 11.130

6.  A crucial role of the PD-1H coinhibitory receptor in suppressing experimental asthma.

Authors:  Huafeng Liu; Xin Li; Li Hu; Min Zhu; Bailin He; Liqun Luo; Lieping Chen
Journal:  Cell Mol Immunol       Date:  2017-05-08       Impact factor: 11.530

7.  VISTA deficiency attenuates antibody-induced arthritis and alters macrophage gene expression in response to simulated immune complexes.

Authors:  Sabrina Ceeraz; Susan K Eszterhas; Petra A Sergent; David A Armstrong; Alix Ashare; Thomas Broughton; Li Wang; Dov Pechenick; Christopher M Burns; Randolph J Noelle; Matthew P Vincenti; Roy A Fava
Journal:  Arthritis Res Ther       Date:  2017-12-08       Impact factor: 5.156

Review 8.  Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family.

Authors:  Frank A Schildberg; Sarah R Klein; Gordon J Freeman; Arlene H Sharpe
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

Review 9.  The structure, expression, and multifaceted role of immune-checkpoint protein VISTA as a critical regulator of anti-tumor immunity, autoimmunity, and inflammation.

Authors:  Wenwen Xu; TạMinh Hiếu; Subramaniam Malarkannan; Li Wang
Journal:  Cell Mol Immunol       Date:  2018-01-29       Impact factor: 11.530

10.  Control of signaling-mediated clearance of apoptotic cells by the tumor suppressor p53.

Authors:  Kyoung Wan Yoon; Sanguine Byun; Eunjeong Kwon; So-Young Hwang; Kiki Chu; Masatsugu Hiraki; Seung-Hee Jo; Astrid Weins; Samy Hakroush; Angelika Cebulla; David B Sykes; Anna Greka; Peter Mundel; David E Fisher; Anna Mandinova; Sam W Lee
Journal:  Science       Date:  2015-07-31       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.